Pharmacology of Recombinant Or Genetically Engineered Drugs

Total Page:16

File Type:pdf, Size:1020Kb

Pharmacology of Recombinant Or Genetically Engineered Drugs Pharmacology Pharmacology of Recombinant or Genetically Engineered Drugs Kamal Kishore, Pawan Krishan1 Departments of Pharmacy, M.J.P. Rohilkhand University, Bareilly-243 006, Uttar Pradesh, 1Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala-147 002, Punjab, India Address for correspondence: Dr. Kamal Kishore; E-mail: [email protected] ABSTRACT Recombinant technology or genetic engineering is a modern method used for the synthesis of therapeutic agents. The central theme of recombinant technology is the process of “gene cloning” which consists of the production of a deÞ ned fragment of DNA and its propagation and ampliÞ cation in a suitable host cell. Drugs developed by recombinant technology or genetic engineering are known as biologics, biopharmaceuticals, recombinant DNA expressed products, bioengineered, or genetically engineered drugs. A current list of various products developed by recombinant technology includes erythropoietin, coagulation modulators, enzymes, hormones, interferons, interleukins, granulocyte colony-stimulating factors, anti-rheumatoid drugs, and various other agents like TNF, becaplermin, hepatitis-B vaccine, antibodies etc. This article provides general as well as recent pharmacological information on different aspects of recombinant drugs that may be useful for their better understanding by users and health care professionals. Key words: Biologics, erythropoietin, interferon, interleukins, insulin, thrombolytic enzymes DOI: 10.4103/0975-1483.55747 INTRODUCTION fragment of DNA and its propagation and ampliÞ cation in a suitable host cell. Recombinant technology was only Drugs developed using living organisms with the help of possible after the discovery of restriction endonucleases, biotechnology or genetic engineering are known as biologics, the enzymes used as cutters for a desired segment[3] of biopharmaceuticals, recombinant DNA expressed genes known as recognition sequences. There are various products, bioengineered, or genetically engineered drugs. other enzymes that have great value in recombinant The recombinant technique was developed by Cohen in technology such as DNA polymerases, ligases, kinases, 1973.[1] The general procedure starts from the identiÞ cation alkaline phosphatases, and nucleases.[4] For thousands of of the gene responsible for the production of the desired years, living microorganisms have been used to produce product. The gene is isolated from human cells and gases, leaven bread, ferment alcoholic liquids, and for other inserted into other carrier or vector cells like bacteria desired by-products, but their use in recombinant DNA (Escherichia coli) or yeast (Saccharomyces cerevisiae, Hansenulla technology is often described as a relatively new science.[5] polymorpha, Pichia pastoris) that proliferate and produce large Recombinant technology, thus, is a new method for the amounts of the desired product.[2] The central theme of development of drugs and other life-saving products that recombinant DNA technology is the process of “gene involves the blending of discoveries in molecular cloning” which consists of the production of a deÞ ned biology, DNA alteration, gene splicing, immunology, J Young Pharm Vol 1 / No 2 141 Kishore and Krishan. J Young Pharm. 2009;1(2):141-150 and immunopharmacology. Now a days, various human CLASSIFICATION OF RECOMBINANT PRODUCTS diseases are treated with the help of drugs developed by recombinant technology, such as erythropoietin, The following products or biologics are obtained by coagulation modulators, enzymes, hormones, interferons, recombinant or genetic engineering technology: interleukins, granulocyte colony-stimulating factors, anti-rheumatoid drugs, and various other agents like (I) Recombinant erythropoietin Tumor necrosis factor (TNF), becaplermin, hepatitis-B Epoetin-α vaccine, antibodies etc. This article provides general as Epoetin-β well as recent pharmacological information on different Epoetin-ω aspects like a brief description of recombinant products, Darbepoetin-α pharmacological actions, mechanism of action, adverse (II) Recombinant blood coagulation modulators effects, doses, contraindications, interactions and (a) Coagulants therapeutic applications. The pharmacological information Factor-VII A of bio-engineered products may be useful for better Factor-VIII understanding by users and professionals in the medical Factor-IX and health-related sciences. (b) Anticoagulants Lepirudin Desirudin MANUFACTURING PROCESS FOR RECOMBINANT Drotecogin alfa PRODUCTS (III) Recombinant enzymes (a) Thrombolytic enzymes The following steps are involved in the production of [4] Alteplase recombinant products: Anistreplase Duteplase Extraction of the DNA from a donor organism and the Reteplase plasmid from bacteria Saruplase ↓ Streptase or streptokinase Cleaved with restriction endonucleases Tenecteplase ↓ Tissue plasminogen activator Joined to form a recombinant DNA molecule or vector Urokinase ↓ (b) Therapeutic enzymes Insert this vector into host cell or expression system Agalsidase beta (E. coli or Yeast) Aeromonas aminopeptidase ↓ Alpha-glactosidase-A Multiplication of recombinant DNA molecules Dornase alpha Imiglucerase or glucocerebrosidase or ↓ alglucerase Formation of clone Laronidase or alpha-L-iduronidase ↓ Galsulfase or N-acetylgalactosamine-4-sulfatase Scale-up (harvesting or fermentation) of cell to produce (IV) Recombinant hormones recombinant drugs (a) Insulin and its analogs ↓ Human insulin PuriÞ cation (centrifugation or Þ ltration) Insulin aspart ↓ Insulin glargine Preformulation Insulin lispro Insulin glulisine ↓ Insulin-like growth factor-I Preclinical studies (animal testing) Insulin-like growth factor-II ↓ (b) Growth hormone and its analogs Clinical studies (human testing) Growth hormone ↓ Growth hormone (ovine) Final product Growth hormone binding protein 142 J Young Pharm Vol 1 / No 2 Pharmacology of recombinant drugs Growth hormone-20K Recombinant albumin Somatrem Fc puriÞ ed recombinant protein Somatropin Becaplermin Sermorelin Beta-nerve growth factor (c) Gonadotropins Bone morphogenetic protein-2 Recombinant follitropin-α Brain-derived neurotrophic factor Recombinant follitropin-β Ciliary neurotrophic factor Recombinant choriogonadotropin Chymosin Follicle-stimulating hormone Endostatin human Luteinizing hormone Enteropeptidase/Enterokinase (d) Other hormones Epidermal growth factors Calcitonin Fibroblast growth factor Glucagon Hepatitis-B vaccine (V) Recombinant interferons Hepatocyte growth factor Interferon alfa-2a Inß uenza A, nucleoprotein, recombinant protein Interferon alfa-2b Lung surfactant protein Interferon beta-1a Relaxin Interferon beta-1b TNF Interferon-gamma-1a Recombinant vaccines Interferon-gamma-1b α-antitrypsin Interferons-ω Thrombopoietin Consensus interferon PHARMACOLOGY OF INDIVIDUAL PRODUCTS (VI) Recombinant interleukins Interleukin-1 alpha Recombinant erythropoietin Interleukin-1 beta [6] Interleukin-2 (aldesleukin) Erythropoietin is a 165 amino acid glycoprotein hormone Interleukin-3 that is synthesized naturally in the kidney and the liver but Interleukin-4 is now prepared by recombinant technology. It stimulates Interleukin-10 erythrocyte formation and is available as epoetin-α, Interleukin-11 (oprelvekin) epoetin-β, and darbepoetin-α. Mechanism of action: It Interleukin-13 stimulates proliferation and differentiation of erythrocytes. Interleukin-15 Dose: 5-100 units/ kg/ s.c. or i.v./three times a week. Interleukin-17 Adverse effects: Allergic reaction, deÞ ciency of iron and folic acid, disorientation, encephalopathy, ß u-like symptoms, Interleukin-18 headache, mild hypertension, seizures, and thrombosis. (VII) Recombinant granulocyte colony stimulating Uses: It is preferred in cases of anemia due to AIDS, cáncer factors chemotherapy, chronic renal failure, and anemia in premature Filgrastim babies. It is also useful in hematopoietic disorders and is used Lenograstim to increase the beneÞ ts of autologous blood transfusión. Molgramostim Sargramostim Recombinant blood coagulation modulators Regrasmostim PegÞ lgrastim Coagulants[7] (VIII) Recombinant anti-rheumatoid agents Factor-VII A is a unique hemostatic agent containing Inß iximab 406 amino acids[8,9] that is supposed to activate the extrinsic Adalimumab pathway of the coagulation cascade.[10] Dose: 150- 500 μg/ kg Basiliximab of body weight. Adverse effects: Factor VIIa may cause Daclizumab adverse effects such as pyrexia, hemorrhage, injection Anakinra site reactions, arthralgia, headache, hypertension, nausea, Etanercept vomiting, pain, edema, and rashes. Uses: It is preferred (IX) Miscellaneous agents in cases of hemophilia-A and B, and in patients with Recombinant antibodies congenital and acquired bleeding abnormalities. J Young Pharm Vol 1 / No 2 143 Kishore and Krishan. J Young Pharm. 2009;1(2):141-150 Factor-VIII is an endogenous glycoprotein coagulating in bleeding, defective homeostasis, trauma, surgical factor that is necessary for blood clotting and hemostasis. procedures, stroke, acute pericarditis, hypoglycemia and It is a cofactor essential for factor IX to activate factor X in hyperglycemia. Dose: 100 mg/i.v. infusion. Adverse effects: the intrinsic pathway. It is a 1438 amino acid peptide that is Alteplase may cause adverse effects like nausea, vomiting, produced in CHO cells. DeÞ ciency of factor VIII causes fever, arrhythmias, allergy, hypotension, intracranial a common inherited bleeding disorder known as hemorrhage, and GIT bleeding. Uses: It is preferred in [11,12] hemophilia-A.
Recommended publications
  • Therapeutic Class Overview Colony Stimulating Factors
    Therapeutic Class Overview Colony Stimulating Factors Therapeutic Class Overview/Summary: This review will focus on the granulocyte colony stimulating factors (G-CSFs) and granulocyte- macrophage colony stimulating factors (GM-CSFs).1-5 Colony-stimulating factors (CSFs) fall under the naturally occurring glycoprotein cytokines, one of the main groups of immunomodulators.6 In general, these proteins are vital to the proliferation and differentiation of hematopoietic progenitor cells.6-8 The G- CSFs commercially available in the United States include pegfilgrastim (Neulasta®), filgrastim (Neupogen®), filgrastim-sndz (Zarxio®), and tbo-filgrastim (Granix®). While filgrastim-sndz and tbo- filgrastim are the same recombinant human G-CSF as filgrastim, only filgrastim-sndz is considered a biosimilar drug as it was approved through the biosimilar pathway. At the time tbo-filgrastim was approved, a regulatory pathway for biosimilar drugs had not yet been established in the United States and tbo-filgrastim was filed under its own Biologic License Application.9 Only one GM-CSF is currently available, sargramostim (Leukine). These agents are Food and Drug Administration (FDA)-approved for a variety of conditions relating to neutropenia or for the collection of hematopoietic progenitor cells for collection by leukapheresis.1-5 Due to the pathway taken, tbo-filgrastim does not share all of the same indications as filgrastim and these two products are not interchangeable. It is important to note that although filgrastim-sndz is a biosimilar product, and it was approved with all the same indications as filgrastim at the time, filgrastim has since received FDA-approval for an additional indication that filgrastim-sndz does not have, to increase survival in patients with acute exposure to myelosuppressive doses of radiation.1-3A complete list of indications for each agent can be found in Table 1.
    [Show full text]
  • FULPHILA Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FULPHILA safely and effectively. See full prescribing information for -----------------------WARNINGS AND PRECAUTIONS----------------------­ FULPHILA. • Fatal splenic rupture: Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture. (5.1) ™ FULPHILA (pegfilgrastim-jmdb) injection, for subcutaneous use • Acute respiratory distress syndrome (ARDS): Evaluate patients who Initial U.S. Approval: 2018 develop fever, lung infiltrates, or respiratory distress. Discontinue ™ ® Fulphila in patients with ARDS. (5.2) FULPHILA (pegfilgrastim-jmdb) is biosimilar* to NEULASTA • Serious allergic reactions, including anaphylaxis: Permanently (pegfilgrastim). (1) discontinue Fulphila in patients with serious allergic reactions. (5.3) • Fatal sickle cell crises: Have occurred. (5.4) ----------------------------INDICATIONS AND USAGE--------------------------- • Glomerulonephritis: Evaluate and consider dose-reduction or Fulphila is a leukocyte growth factor indicated to interruption of Fulphila if causality is likely. (5.5) • Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving ------------------------------ADVERSE REACTIONS------------------------------ myelosuppressive anti-cancer drugs associated with a clinically Most common adverse reactions (≥ 5% difference in incidence compared to significant incidence of febrile neutropenia.
    [Show full text]
  • Sargramostim (Leukine®)
    Policy Medical Policy Manual Approved Revision: Do Not Implement until 8/31/21 Sargramostim (Leukine®) NDC CODE(S) 71837-5843-XX LEUKINE 250MCG Solution Reconstituted (PARTNER THERAPEUTICS) DESCRIPTION Sargramostim is a recombinant human granulocyte-macrophage colony stimulating factor (rGM-CSF) produced by recombinant DNA technology in a yeast (S. cerevisiae) expression system. Like endogenous GM-CSF, rGM-CSF is a hematopoietic growth factor which stimulates proliferation and differentiation of hematopoietic progenitor cells in the granulocyte-macrophage pathways which include neutrophils, monocytes/macrophages and myeloid-derived dendritic cells. It is also capable of activating mature granulocytes and macrophages. Various cellular responses such as division, maturation and activation are induced by GM-CSF binding to specific receptors expressed on the cell surface of target cells. POLICY Sargramostim for the treatment of the following is considered medically necessary: o Acute myelogenous leukemia following induction or consolidation chemotherapy o Bone Marrow Transplantation (BMT) failure or Engraftment Delay o Individuals acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome [H-ARS]) o Myeloid reconstitution after autologous or allogeneic bone marrow transplant (BMT) o Peripheral Blood Progenitor Cell (PBPC) mobilization and transplant Sargramostim for the treatment of chemotherapy-induced febrile neutropenia is considered medically necessary if the medical appropriateness
    [Show full text]
  • • All Doacs Are Cleared to Some Extent by the Kidneys
    • All DOACs are cleared to some extent by the kidneys – Dabigatran 80% – Rivaroxaban 33% – Apixaban 25% – Potential for drug accumulation in patients with severe renal impairment especially below eGFRs <30 Warfarin is unaffected by renal impairment (only • Rivaroxaban & Apixaban are both oral direct inhibitor of factor Xa. • Rivaroxaban doses recommended for clinical use are 15mg od and 20 mg od (15 mg bd for first 3 weeks of treatment of DVT). • Apixaban 5mg bd or 2.5mg bd • Rivaroxaban peak plasma levels are reached 2 to 3 h after ingestion • Apixaban peak plasma levels are reached ~3hrs after ingestion • Rivaroxaban is taken with food – Apixaban without food • Rivaroxaban is 33% renaly excreted and has a half-life of 9 h in patients with normal renal function. – There is an analogy with Therapeutic LMWH – We very rarely ask for an anti-Xa assay • And what is the clinical significance of a Xa assay ? (Cut off values are largely arbitrary) – Fixed doses – Importance of When the last dose was taken ? – Importance of What is the renal function ? – If bleeding • What is the nature of the bleeding ? • In extremis we can give protamine sulphate (? Efficacy) • How to manage bleeding on a DOAC? –How severe is the bleeding ? –When was the last dose of medication ? –What is the renal function ? – Recheck –If minor bleeding; epistaxis, gingival, bruising, menorrhagia • Withhold the NOAC (when was the last dose taken?) • Recheck renal function • Check FBC • Local measures • Unlikely to require further intervention – Re-challenge – ? Switch NOAC
    [Show full text]
  • Low Molecular Weight Heparins and Heparinoids
    NEW DRUGS, OLD DRUGS NEW DRUGS, OLD DRUGS Low molecular weight heparins and heparinoids John W Eikelboom and Graeme J Hankey UNFRACTIONATED HEPARIN has been used in clinical ABSTRACT practice for more than 50 years and is established as an effective parenteral anticoagulant for the prevention and ■ Several low molecular weight (LMW) heparin treatment of various thrombotic disorders. However, low preparations, including dalteparin, enoxaparin and molecularThe Medical weight Journal (LMW) of heparinsAustralia haveISSN: recently 0025-729X emerged 7 October as nadroparin, as well as the heparinoid danaparoid sodium, more2002 convenient, 177 6 379-383 safe and effective alternatives to unfrac- are approved for use in Australia. 1 tionated©The heparin Medical (BoxJournal 1). of AustraliaIn Australia, 2002 wwwLMW.mja.com.au heparins are ■ LMW heparins are replacing unfractionated heparin for replacingNew Drugs,unfractionated Old Drugs heparin for preventing and treating the prevention and treatment of venous thromboembolism venous thromboembolism and for the initial treatment of and the treatment of non-ST-segment-elevation acute unstable acute coronary syndromes. The LMW heparinoid coronary syndromes. danaparoid sodium is widely used to treat immune heparin- ■ induced thrombocytopenia. The advantages of LMW heparins over unfractionated heparin include a longer half-life (allowing once-daily or twice-daily subcutaneous dosing), high bioavailability and Limitations of unfractionated heparin predictable anticoagulant response (avoiding the need
    [Show full text]
  • Comparison Between Filgrastim and Lenograstim Plus Chemotherapy For
    Bone Marrow Transplantation (2010) 45, 277–281 & 2010 Macmillan Publishers Limited All rights reserved 0268-3369/10 $32.00 www.nature.com/bmt ORIGINAL ARTICLE Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs R Ria, T Gasparre, G Mangialardi, A Bruno, G Iodice, A Vacca and F Dammacco Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy Recombinant human (rHu) G-CSF has been widely used during transplantation.4 However, the use of G-CSF after to treat neutropenia and mobilize PBPCs for their autologous PBPC transplantation has been queried, as its autologous and allogeneic transplantation. It shortens further reduction in time to a safe neutrophil count5,6 does neutropenia and thus reduces the frequency of neutropenic not always imply fewer significant clinical events, such as fever. We compared the efficiency of glycosylated rHu infections, length of hospitalization, extrahematological and non-glycosylated Hu G-CSF in mobilizing hemato- toxicities or mortality.7,8 Even so, the ASCO guidelines still poietic progenitor cells (HPCs). In total, 86 patients were recommend the use of growth factors after autologous consecutively enrolled for mobilization with CY plus either PBPC transplantation.9 glycosylated or non-glycosylated G-CSF, and under- G-CSF induces the proliferation and differentiation of went leukapheresis. The HPC content of each collection, myeloid precursor cells, and also provides a functional toxicity, days of leukapheresis needed to reach the activity that influences chemotaxis, respiratory burst and minimum HPC target and days to recover WBC (X500 Ag expression of neutrophils.
    [Show full text]
  • Regenerative Mechanisms and Novel Therapeutic Approaches
    brain sciences Review Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches Rashad Hussain 1,*, Hira Zubair 2, Sarah Pursell 1 and Muhammad Shahab 2,* 1 Center for Translational Neuromedicine, University of Rochester, NY 14642, USA; [email protected] 2 Department of Animal Sciences, Quaid-i-Azam University, Islamabad 45320, Pakistan; [email protected] * Correspondence: [email protected] (R.H.); [email protected] (M.S.); Tel.: +1-585-276-6390 (R.H.); +92-51-9064-3014 (M.S.) Received: 13 July 2018; Accepted: 12 September 2018; Published: 15 September 2018 Abstract: Regeneration refers to regrowth of tissue in the central nervous system. It includes generation of new neurons, glia, myelin, and synapses, as well as the regaining of essential functions: sensory, motor, emotional and cognitive abilities. Unfortunately, regeneration within the nervous system is very slow compared to other body systems. This relative slowness is attributed to increased vulnerability to irreversible cellular insults and the loss of function due to the very long lifespan of neurons, the stretch of cells and cytoplasm over several dozens of inches throughout the body, insufficiency of the tissue-level waste removal system, and minimal neural cell proliferation/self-renewal capacity. In this context, the current review summarized the most common features of major neurodegenerative disorders; their causes and consequences and proposed novel therapeutic approaches. Keywords: neuroregeneration; mechanisms; therapeutics; neurogenesis; intra-cellular signaling 1. Introduction Regeneration processes within the nervous system are referred to as neuroregeneration. It includes, but is not limited to, the generation of new neurons, axons, glia, and synapses. It was not considered possible until a couple of decades ago, when the discovery of neural precursor cells in the sub-ventricular zone (SVZ) and other regions shattered the dogma [1–4].
    [Show full text]
  • Filgrastim Vs Pegfilgrastim: a Quality of Life Issue for Children
    FEATURE | Filgrastim vs pegfilgrastim Filgrastim vs pegfilgrastim: A quality of life issue for children Administration, safety, and efficacy are similar in both agents.H owever, the frequency of administration makes a significant difference for patients. KAREN E. MACDonaLD, BSN, RN, CPON; HAYLEY BEE, BSN, RN, CPN, CCRN; DARBY TOZER, BSN, RN; JEnnIFER E. TRAIN, BSN, RN ancer is diagnosed in 1.5 million people in the United States each year, and more than 12,000 cancer patients are younger C 1 than 21 years. Parents sit across the table from the medical team and learn about the side effects of treatment that their child may experience. The child will lose his or her hair, miss school, experience nausea and vomiting, and endure multiple laboratory and diagnostic tests. Families learn that their day-to-day life, once filled with school, work, soccer games, and other family- centered activities, will now consist of hospital admissions, doctor visits, and isolation to abate the possible side effects of treatment. In addition, parents will need to learn how to administer clinical care, such as subcutaneous injections of medications to improve the child’s immune system, at home. Neutrophils are a critical member of the phago- cytic system and provide a first-line defense against bacterial organisms.2 Neutropenia is defined as a reduction in circulating neutrophils to less than 1,500/µL.1 Chemotherapy-induced neutropenia is the primary treatment-related dose-limiting toxicity in children with can- cer. Severe neutropenia (neutrophils less than 500/µL) can occur as a result of chemotherapy treatment. Children who receive intensive che- motherapy have a 40% chance of developing 3 © THINKSTOCK © febrile neutropenia.
    [Show full text]
  • THE CONCISE GUIDE to PHARMACOLOGY 2017/18 Alexander, Stephen P
    University of Dundee THE CONCISE GUIDE TO PHARMACOLOGY 2017/18 Alexander, Stephen P. H.; Fabbro, Doriano; Kelly, Eamonn; Marrion, Neil V.; Peters, John A.; Faccenda, Elena Published in: British Journal of Pharmacology DOI: 10.1111/bph.13876 Publication date: 2017 Licence: CC BY Document Version Publisher's PDF, also known as Version of record Link to publication in Discovery Research Portal Citation for published version (APA): Alexander, S. P. H., Fabbro, D., Kelly, E., Marrion, N. V., Peters, J. A., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A., & CGTP Collaborators (2017). THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Catalytic receptors. British Journal of Pharmacology, 174 (Suppl. 1), S225-S271. https://doi.org/10.1111/bph.13876 General rights Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain. • You may freely distribute the URL identifying the publication in the public portal. Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 23. Sep. 2021 S.P.H.
    [Show full text]
  • The Impact of Biosimilar Competition in Europe December 2020
    White Paper The Impact of Biosimilar Competition in Europe December 2020 PER TROEIN, Vice President, Strategic Partners, IQVIA MAX NEWTON, Senior Consultant, Global Supplier & Association Relations, IQVIA KIRSTIE SCOTT, Analyst, Global Supplier & Association Relations, IQVIA Table of contents Introduction 1 Key observations 2 Methodology 11 Country and therapy area KPIs 14 Human growth hormone (HGH) 14 Epoetin (EPO) 16 Granulocyte-colony stimulating factor (GCSF) 18 Anti-tumour necrosis factor (ANTI-TNF) 20 Fertility (FOLLITROPIN ALFA) 22 Insulins 24 Oncology 26 Low-molecular-weight heparin (LMWH) 28 Appendix 30 EMA list of approved biosimilars 30 List of Biosimilars under review by EMA 32 Introduction ‘The Impact of Biosimilar Competition in Europe’ report describes the effects on price, volume, and market share following the arrival of biosimilar competition in Europe. The report consists of: observations on competitive markets, and a set of Key Performance Indicators (KPIs) to monitor the impact of biosimilars in 23 European markets. The report has been a long-standing source of information on the status of the biosimilars market. This iteration has been delayed due to the COVID-19 pandemic across the globe and has provided an opportunity to provide full-year 2019 data, and an additional data point (June 2020 MAT) which incorporates the impact on patients in Europe across major therapeutic areas to 30th June 2020. The direct impact of which is visible in the Low Molecular Weight Heparin (LMWH), and Fertility (somatropin) markets. This report has been prepared by IQVIA at the The European Medicines Agency (EMA) has a central request of the European Commission services with role in setting the rules for biosimilar submissions, initial contributions on defining the KPIs from EFPIA, approving applications, establishing approved Medicines for Europe, and EuropaBio.
    [Show full text]
  • Anticoagulation Reversal Guideline for Adults
    Anticoagulation Reversal Guideline for Adults Antithrombotic reversal strategies should be limited to clinical situations (i.e. life-threatening bleeding) where the immediate need for anticoagulant reversal outweighs the risk of thrombosis (either from the reversal agent itself or normalization of coagulation in a patient with underlying thromboembolic risk). These recommendations are meant to serve as general guidelines and should not replace clinical judgment. Always seek input from the appropriate specialists when indicated and include the patient and/or family in shared decision making when possible. This document is not meant to guide selection of patients for reversal therapies. Please refer to appropriate national guidelines to aide decision- making regarding need for reversal, if warranted. 1. ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants 2. Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine All indications for anticoagulation are considered, including atrial fibrillation, venous thromboembolism, prosthetic cardiac valves, and intracardiac thrombus. Mechanical circulatory support devices, including temporary or permanent ventricular assist devices (i.e. LVADs), are excluded from this document. Whenever possible, anticoagulation should be resumed in a timely manner to avoid thromboembolic complications related to the underlying indication for anticoagulation. This guideline does not provide recommendations on resuming anticoagulation. References: • Tomaselli GF, Mahaffey KW, Cuker A, et al. 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Experts Consensus Decisions Pathways. J Am Coll Cardiol.
    [Show full text]
  • Sargramostim (Leukine) Reference Number: CP.PHAR.295 Effective Date: 12/16 Coding Implications Last Review Date: 10/16 Revision Log
    Clinical Policy: Sargramostim (Leukine) Reference Number: CP.PHAR.295 Effective Date: 12/16 Coding Implications Last Review Date: 10/16 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description The intent of the criteria is to ensure that patients follow selection elements established by Centene® clinical policy for sargramostim (Leukine® injection, for subcutaneous or intravenous use). Policy/Criteria It is the policy of health plans affiliated with Centene Corporation® that Leukine is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Acute Myeloid Leukemia (must meet all): 1. Leukine is prescribed for use following induction therapy for acute myeloid leukemia (AML); 2. Member has none of the following contraindications: a. Excessive leukemic myeloid blasts in the bone marrow/peripheral blood (≥ 10%); b. Known hypersensitivity to granulocyte-macrophage colony stimulating factor (GM-CSF), yeast-derived products or any component of the product; c. Concomitant use with chemotherapy/radiotherapy. Approval duration: 6 months B. Peripheral Blood Progenitor Cell Collection and Transplantation (must meet all): 1. Leukine is prescribed for either of the following: a. Mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis in anticipation of transplantation after myeloablative chemotherapy; b. Following myeloablative chemotherapy and transplantation of autologous hematopoietic progenitor cells; 2. Member has none of the following contraindications: a. Excessive leukemic myeloid blasts in the bone marrow/ peripheral blood (≥ 10%); b. Known hypersensitivity to GM-CSF, yeast-derived products or any component of the product; c. Concomitant use with chemotherapy/radiotherapy. Approval duration: 6 months C.
    [Show full text]